Home
CSTL
CSTL News

Latest Castle Biosciences Inc. (CSTL) News on April 2, 2025

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

GlobeNewswire

4 days ago

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Business Wire

a month ago

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business

Simply Wall St.

a month ago

Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business

What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing?

Simply Wall St.

a month ago

What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing?

Thomson Reuters StreetEvents

a month ago

Q4 2024 Castle Biosciences Inc Earnings Call

Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

a month ago

Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates

Zacks

a month ago

Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates

Business Wire

a month ago

Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings

GuruFocus.com

a month ago

What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings

Castle Biosciences to Participate in Upcoming Investor Conferences

Business Wire

a month ago

Castle Biosciences to Participate in Upcoming Investor Conferences

CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know

Zacks

a month ago

CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

a month ago

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth

Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?

Zacks

a month ago

Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?

Business Wire

2 months ago

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®

Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock

Zacks

2 months ago

Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock

Castle Biosciences (CSTL) Upgraded to Buy: Here's Why

Zacks

2 months ago

Castle Biosciences (CSTL) Upgraded to Buy: Here's Why

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Zacks

2 months ago

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

Zacks

2 months ago

Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Zacks

2 months ago

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

Business Wire

2 months ago

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss

Simply Wall St.

2 months ago

Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss

Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet

Zacks

2 months ago

Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet

FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication

Zacks

2 months ago

FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

Zacks

2 months ago

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss

Zacks

2 months ago

NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss

4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now

Zacks

2 months ago

4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now

Castle’s Poster on DecisionDx®-SCC Selected as a "Late Breakers" Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

Business Wire

3 months ago

Castle’s Poster on DecisionDx®-SCC Selected as a "Late Breakers" Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Zacks

3 months ago

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study

Zacks

3 months ago

Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study

Business Wire

3 months ago

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

Zacks

3 months ago

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

Zacks

3 months ago

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

Zacks

3 months ago

CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

Zacks

3 months ago

FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs

Zacks

3 months ago

AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

Castle Biosciences gains New York state approval for Barrett’s oesophagus test

Medical Device Network

3 months ago

Castle Biosciences gains New York state approval for Barrett’s oesophagus test

MT Newswires

3 months ago

Castle Biosciences Says TissueCypher Test Approved by New York Health Department

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

Business Wire

3 months ago

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Zacks

3 months ago

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Zacks

3 months ago

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Zacks

3 months ago

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Neumora Stock Hits Record Low on Depression Drug Study Failure

Zacks

3 months ago

Neumora Stock Hits Record Low on Depression Drug Study Failure

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

Zacks

3 months ago

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

Zacks

3 months ago

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Zacks

3 months ago

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Castle Biosciences reports preliminary data from atopic dermatitis test study

Medical Device Network

3 months ago

Castle Biosciences reports preliminary data from atopic dermatitis test study

Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek

Zacks

3 months ago

Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek

Business Wire

3 months ago

Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Zacks

3 months ago

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder

Zacks

3 months ago

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Merck Ends Development of Two Experimental Cancer Drugs

Zacks

4 months ago

Merck Ends Development of Two Experimental Cancer Drugs

4 Solid Net Profit Margin Stocks to Boost Portfolio Returns

Zacks

4 months ago

4 Solid Net Profit Margin Stocks to Boost Portfolio Returns

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

Zacks

4 months ago

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Zacks

4 months ago

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade

Zacks

4 months ago

Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

Zacks

4 months ago

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Zacks

4 months ago

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma

Business Wire

4 months ago

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma

Here's Why Agios Stock Plummeted More Than 20% on Monday

Zacks

4 months ago

Here's Why Agios Stock Plummeted More Than 20% on Monday

AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal

Zacks

4 months ago

AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal

GSK Expands Vaccine Collaboration With Zhifei in China

Zacks

4 months ago

GSK Expands Vaccine Collaboration With Zhifei in China

JANX Stock Hits Record High on Prostate Cancer Study Data

Zacks

4 months ago

JANX Stock Hits Record High on Prostate Cancer Study Data

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Zacks

4 months ago

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Grifols Stock Declines After Brookfield Drops Buyout Offer

Zacks

4 months ago

Grifols Stock Declines After Brookfield Drops Buyout Offer

Small Caps Are Winners of 2024: 5 Picks With Solid Short-Term Upside

Zacks

4 months ago

Small Caps Are Winners of 2024: 5 Picks With Solid Short-Term Upside

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

Zacks

4 months ago

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks

4 months ago

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Zacks

4 months ago

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Business Wire

4 months ago

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

Zacks

4 months ago

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

Business Wire

4 months ago

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

Zacks

4 months ago

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Zacks

5 months ago

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

Zacks

5 months ago

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.

5 months ago

Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest

Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

5 months ago

Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

Business Wire

5 months ago

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why

Zacks

5 months ago

Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why

Castle boasts melanoma test’s capacity to reduce unnecessary testing

Medical Device Network

5 months ago

Castle boasts melanoma test’s capacity to reduce unnecessary testing

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test

Business Wire

5 months ago

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test

Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024

Business Wire

5 months ago

Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024

Castle Biosciences price target raised to $39 from $37 at Baird

TipRanks

5 months ago

Castle Biosciences price target raised to $39 from $37 at Baird

Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations

Castle Biosciences price target raised to $36 from $28 at KeyBanc

TipRanks

5 months ago

Castle Biosciences price target raised to $36 from $28 at KeyBanc

MT Newswires

5 months ago

Castle Biosciences Insider Sold Shares Worth $273,251, According to a Recent SEC Filing

Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

5 months ago

Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates

Zacks

5 months ago

Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates

Castle Biosciences Reports Third Quarter 2024 Results

Business Wire

5 months ago

Castle Biosciences Reports Third Quarter 2024 Results

Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?

Zacks

5 months ago

Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?

Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: What To Expect

GuruFocus.com

5 months ago

Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: What To Expect

Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients

Business Wire

5 months ago

Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients

Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

5 months ago

Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Castle Biosciences to Participate in Upcoming Investor Conferences

Business Wire

5 months ago

Castle Biosciences to Participate in Upcoming Investor Conferences

Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going

Zacks

5 months ago

Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going

Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?

Zacks

5 months ago

Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?

MT Newswires

5 months ago

Castle Biosciences Says Data Shows Efficacy of its Skin Cancer Tests

Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors

Business Wire

5 months ago

Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors

Business Wire

6 months ago

Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential

Share on Social Networks: